Clinical and Molecular Study to Evaluate the Effect of the Pixel CO2 Laser (FemiLiftTM) for the Treatment of Vulvo-Vaginal Atrophy

NCT07024667 | Recruiting DMC

• 1 other identifier: 0001-21-HYMC
• Study Type: interventional
• Target: 20
• Locations: 1 country
• Sites: 1

Brief Summary

Vulvo Vaginal Atrophy (VVA) refers to the changes in the vaginal and vulvar surfaces that occurs during menopause due to the progressive loss of estrogen. The low levels of circulating estrogen produce a wide variety of anatomic, physiologic, and clinical changes in the urogenital area. Clinical symptoms include vaginal dryness, irritation, soreness, dyspareunia, dysuria, and vaginal discharge. In recent years, microablative fractional CO2 laser has become available for treating vaginal atrophy. It showed a regenerative property with significant histological changes in cellular and connective tissue components. Treatment with the fractional CO2 laser resulted in restoration of the vaginal epithelium with ultrastructural findings, similar to a premenopausal state, that included thickened stratified squamous epithelium with increased collagen support, increased glycogen in epithelial cells, increased fibroblasts, increased vascularity, and presence of sub-epithelial papillae.

Conditions

Vulvar Atrophy; Vaginal Atrophy

Outcome Measures

Primary Outcomes (2)

• To evaluate the efficacy of Pixel CO2 laser (FemiLift™) for the treatment of VVA via the patient symptoms and complaints.

  The efficacy of Pixel CO2 laser (FemiLift™) treatment will be evaluate by: 1. Improvement in VVA symptoms (itching, burning, dryness, dyspareunia, and dysuria) as evaluated by the subject, using a Numeric Rating Scales (NRSs) of 0-10. 2. Improvement in sexual function as evaluated by the subject, using the Female Sexual Function Index (FSFI)

  Two years

• To evaluate gene expression following the FemiLiftTM treatment

  Changes in gene expression profile, 2 weeks following the third FemiLiftTM treatment (Tx3), compared to baseline. The list of genes chosen for RT PCR following a CO2 laser treatment on vaginal mucosa, includes genes taken from the following biological pathways: inflammatory response, wound healing, extracellular remodeling and connective tissue formation.

  Two years

Study Arms (1)

Study intervention group

EXPERIMENTAL

Patients who has vulvo-vaginal atrophy

Device: Pixel CO2 Laser for the Treatment of Vulvo-Vaginal Atrophy (VVA)

Interventions

Pixel CO2 Laser for the Treatment of Vulvo-Vaginal Atrophy (VVA) DEVICE

Pixel CO2 Laser for the Treatment of Vulvo-Vaginal Atrophy (VVA)

Study intervention group

Eligibility Criteria

• Age: 45 Years - 75 Years
• Gender Eligibility Details: Patients that suffers from Vulvo-Vaginal Atrophy (VVA)
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Female 45-75 years of age, at the time of enrolment.
• Provided written informed consent.
• Spontaneous induced menopause as defined by one of the followings:
• Amenorrhea of ≥12 months
• After bilateral oophorectomy
• FSH levels\>30 IU
• One or more VVA related symptoms (i.e., itching, dryness, burning, pain, dyspareunia, or dysuria), after other possible causes of these complaints have been excluded.
• Characteristic atrophic changes (see above) on gynaecological examination.
• Normal Papanicolaou (PAP) smear test from the last 3-5 years: if needed and as indicated according to the Israeli guidelines.
• Negative urine analysis test - urine stick.
• Asymptomatic for bacterial or fungal vaginitis.
• Vaginal canal, introitus and vestibule free of injuries and bleeding.
• Able and willing to comply with the treatment/ follow-up schedule and requirements.
• Normal general gynecological exam from the last year including US.

You may not qualify if:

• Vaginal Health Index Score (VHIS) \< 5.
• Active genital infection.
• Vaginal bleeding which did not underwent evaluation.
• Previous vulvar, vaginal or cervical dysplasia, within the last 2 years, or previous cancer.
• Recurring urinary tract infection or recurring infection of genital herpes (≥ 3 episodes in the recent year).
• Pelvic Organ prolapse (POP) \>II, according to the pelvic organ prolapse quantification system (POP-Q).
• Serious systemic disease or any chronic condition that could interfere with study compliance.
• Any local, systemic and/or chronic autoimmune infection.
• Taken part in a clinical trial concerning VVA, within 30 days prior to the enrolment.
• Allergy to lidocaine or tetracaine.
• Genital skin disease that may interfere with the treatment (these subjects should be included/excluded according to the investigator's discretion).
• Use of anticoagulants, within 5 days prior to enrolment.
• Active positive HPV test.
• Active positive HSV (Acute or actively present within the last 2 months).
• Heavy smoker (\>1 pack of cigarettes a day)

Sponsors & Collaborators

• Hillel Yaffe Medical Center: lead

Study Sites (1)

Hille Yaffe Medical Center

Hadera, 3881000, Israel

RECRUITING

Study Officials

• Jonia Alsheik, MD

  Hillel Yaffe Medical Center

  PRINCIPAL INVESTIGATOR

Central Study Contacts

Jonia Alsheik, MD

CONTACT

+972-4-7744602; osnatp@hymc.gov.il

Osnat Palgi mirochnik, RN, BSc

CONTACT

+972-4-7744602

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER GOV
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: May 19, 2025
• First Posted: June 17, 2025
• Study Start: September 2, 2022
• Primary Completion (Estimated): December 31, 2027
• Study Completion (Estimated): December 31, 2027
• Last Updated: June 17, 2025

Record last verified: 2025-06

Locations

IL (1)